182 related articles for article (PubMed ID: 20980999)
1. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Heath EI; Chiorean EG; Sweeney CJ; Hodge JP; Lager JJ; Forman K; Malburg L; Arumugham T; Dar MM; Suttle AB; Gainer SD; LoRusso P
Clin Pharmacol Ther; 2010 Dec; 88(6):818-23. PubMed ID: 20980999
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
5. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Altorki N; Lane ME; Bauer T; Lee PC; Guarino MJ; Pass H; Felip E; Peylan-Ramu N; Gurpide A; Grannis FW; Mitchell JD; Tachdjian S; Swann RS; Huff A; Roychowdhury DF; Reeves A; Ottesen LH; Yankelevitz DF
J Clin Oncol; 2010 Jul; 28(19):3131-7. PubMed ID: 20516450
[TBL] [Abstract][Full Text] [Related]
6. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
7. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
Rubin EH; Agrawal NG; Friedman EJ; Scott P; Mazina KE; Sun L; Du L; Ricker JL; Frankel SR; Gottesdiener KM; Wagner JA; Iwamoto M
Clin Cancer Res; 2006 Dec; 12(23):7039-45. PubMed ID: 17145826
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
Rugo HS; Herbst RS; Liu G; Park JW; Kies MS; Steinfeldt HM; Pithavala YK; Reich SD; Freddo JL; Wilding G
J Clin Oncol; 2005 Aug; 23(24):5474-83. PubMed ID: 16027439
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
10. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads.
Damle BD; Yan JH; Behr D; O'Mara E; Nichola P; Kaul S; Knupp C
J Clin Pharmacol; 2002 Apr; 42(4):419-27. PubMed ID: 11936567
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
12. Effect of food on the pharmacokinetics of rosuvastatin after administration of a single oral dose in dogs.
Baek IH; Kwon KI; Kim MS
Drug Res (Stuttg); 2013 Mar; 63(3):145-9. PubMed ID: 23447089
[TBL] [Abstract][Full Text] [Related]
13. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
Henney HR; Shah J
Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of pazopanib administered in combination with bevacizumab.
Imbs DC; Négrier S; Cassier P; Hollebecque A; Varga A; Blanc E; Lafont T; Escudier B; Soria JC; Pérol D; Chatelut E
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1189-96. PubMed ID: 24705975
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Pithavala YK; Chen Y; Toh M; Selaru P; LaBadie RR; Garrett M; Hee B; Mount J; Ni G; Klamerus KJ; Tortorici MA
Cancer Chemother Pharmacol; 2012 Jul; 70(1):103-12. PubMed ID: 22644797
[TBL] [Abstract][Full Text] [Related]
16. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin).
Zimmerman JJ; Ferron GM; Lim HK; Parker V
J Clin Pharmacol; 1999 Nov; 39(11):1155-61. PubMed ID: 10579146
[TBL] [Abstract][Full Text] [Related]
17. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
Heath EI; Forman K; Malburg L; Gainer S; Suttle AB; Adams L; Ball H; LoRusso P
Invest New Drugs; 2012 Aug; 30(4):1566-74. PubMed ID: 21811833
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.
Paulson SK; Vaughn MB; Jessen SM; Lawal Y; Gresk CJ; Yan B; Maziasz TJ; Cook CS; Karim A
J Pharmacol Exp Ther; 2001 May; 297(2):638-45. PubMed ID: 11303053
[TBL] [Abstract][Full Text] [Related]
19. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
Lincoln J; Stewart ME; Preskorn SH
J Psychiatr Pract; 2010 Mar; 16(2):103-14. PubMed ID: 20511734
[TBL] [Abstract][Full Text] [Related]
20. Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study.
Scallion R; Moore KA
Clin Ther; 2009 Oct; 31(10):2233-41. PubMed ID: 19922894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
